Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice
| Main Author: | |
|---|---|
| Publication Date: | 2024 |
| Other Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | eng |
| Source: | Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| Download full: | http://hdl.handle.net/10362/172566 |
Summary: | Publisher Copyright: © 2024 Sociedade Portuguesa de Cardiologia |
| id |
RCAP_271da7a252362bf8524bc6ec59651be9 |
|---|---|
| oai_identifier_str |
oai:run.unl.pt:10362/172566 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| repository_id_str |
https://opendoar.ac.uk/repository/7160 |
| spelling |
Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practiceDapagliflozinEconomic burdenHealthcare costsHeart failureHF hospitalizationSGLT2iCardiology and Cardiovascular MedicinePublisher Copyright: © 2024 Sociedade Portuguesa de CardiologiaIntroduction and objectives: Heart failure (HF) is a clinical syndrome associated with substantial morbidity, mortality, and healthcare costs. Dapagliflozin has proven efficacy in reducing the risk of death and hospitalization in HF patients, regardless of left ventricular ejection fraction (LVEF). This paper aimed to project the potential impact of dapagliflozin on healthcare costs related to HF subsequent hospitalizations (HFHs) in Portuguese hospitals. Methods: The total number of HF-related hospitalizations (hHF), HFHs, and the average length of stay for patients with a primary diagnosis of HF from six Portuguese hospitals, between January 2019 and December 2021, were collected and aggregated by hospital classification. Costs associated with HFHs were calculated according to Portuguese legislation and considering conservative, average, and complex approaches. Cost-saving projections were based on extrapolations from hHF risk reductions reported in dapagliflozin clinical trials. Results: Considering a 26% risk reduction in hHF reported on pooled-analysis of DAPA-HF and DELIVER as the expected reduction in HFHs, the use of dapagliflozin would be associated with cost savings ranging from EUR 1 612 851.54 up to EUR 6 587 360.09, when considering all hospitals and the different approaches, between 2019 and 2021. A similar projection is observed based on 24% RRR derived by weighting DAPA-HF and DELIVER sub-analyses and PORTHOS epidemiological data. Conclusions: In this projection, dapagliflozin use in all eligible hHF patients is associated with a significant reduction in direct costs. Our data support that, in addition to the improvements in HF-related outcomes, dapagliflozin may have a significant economic impact on healthcare costs in Portuguese hospitals.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNBrito, DulceFonseca, CândidaFranco, FátimaLopes, VanessaGonçalves, SaraBaptista, RuiSequeira, JoanaMarques, IreneRego, RitaPimenta, JoanaSilva-Cardoso, JoséLopes, MargaridaAlmeida, Mário2024-09-27T22:22:29Z2024-122024-12-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/172566eng0870-2551PURE: 99182436https://doi.org/10.1016/j.repc.2024.04.012info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-04-14T01:37:52Zoai:run.unl.pt:10362/172566Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T18:54:29.737092Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse |
| dc.title.none.fl_str_mv |
Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice |
| title |
Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice |
| spellingShingle |
Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice Brito, Dulce Dapagliflozin Economic burden Healthcare costs Heart failure HF hospitalization SGLT2i Cardiology and Cardiovascular Medicine |
| title_short |
Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice |
| title_full |
Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice |
| title_fullStr |
Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice |
| title_full_unstemmed |
Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice |
| title_sort |
Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice |
| author |
Brito, Dulce |
| author_facet |
Brito, Dulce Fonseca, Cândida Franco, Fátima Lopes, Vanessa Gonçalves, Sara Baptista, Rui Sequeira, Joana Marques, Irene Rego, Rita Pimenta, Joana Silva-Cardoso, José Lopes, Margarida Almeida, Mário |
| author_role |
author |
| author2 |
Fonseca, Cândida Franco, Fátima Lopes, Vanessa Gonçalves, Sara Baptista, Rui Sequeira, Joana Marques, Irene Rego, Rita Pimenta, Joana Silva-Cardoso, José Lopes, Margarida Almeida, Mário |
| author2_role |
author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) RUN |
| dc.contributor.author.fl_str_mv |
Brito, Dulce Fonseca, Cândida Franco, Fátima Lopes, Vanessa Gonçalves, Sara Baptista, Rui Sequeira, Joana Marques, Irene Rego, Rita Pimenta, Joana Silva-Cardoso, José Lopes, Margarida Almeida, Mário |
| dc.subject.por.fl_str_mv |
Dapagliflozin Economic burden Healthcare costs Heart failure HF hospitalization SGLT2i Cardiology and Cardiovascular Medicine |
| topic |
Dapagliflozin Economic burden Healthcare costs Heart failure HF hospitalization SGLT2i Cardiology and Cardiovascular Medicine |
| description |
Publisher Copyright: © 2024 Sociedade Portuguesa de Cardiologia |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024-09-27T22:22:29Z 2024-12 2024-12-01T00:00:00Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/172566 |
| url |
http://hdl.handle.net/10362/172566 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
0870-2551 PURE: 99182436 https://doi.org/10.1016/j.repc.2024.04.012 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia instacron:RCAAP |
| instname_str |
FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| collection |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
| repository.name.fl_str_mv |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
| repository.mail.fl_str_mv |
info@rcaap.pt |
| _version_ |
1833597748287373312 |